On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Stratec Biomedical AG Gemini. This instrumentation change is necessary as Bio-Rad is discontinuing service on our existing QuickStep instrumentation.
Although the Immucor assay and sample requirements will remain the same, the package insert has been modified to state the assay is specific to the Stratec Gemini instrument. The new package insert, assay history list, and platform history list will be available on the CTS website on 04/29/19.
Just a reminder that the revised client forms implement today! Don't forget to toss your o...
On July 6, 2018 the FDA released an industry guidance document for transitioning from individual to ...
The recent communication regarding the recent Anti-SARS-CoV-2 Total assay in Tampa has brought about...
This is the first update to the original CTS communication distributed on July 6th. As previously co...
On February 18, 2019, the new CTS Laboratory Information System was successfully implemented in Tamp...
IPFA welcomes Marion Lanteri as Executive Board member, CTS as new member organization